Nuvation Bio Stock Earnings Reports

Nuvation Bio reported its first full commercial quarter following FDA approval of IBTROZI (taletrectinib). Key commercial metrics: 204 new patient starts in Q3 (over 15/week), $13.1M total revenue for the quarter including $7.7M net product revenue from IBTROZI, and payer coverage exceeding 80% of covered lives. Clinical data highlights: pooled TRUST-I/II data median duration of response (DOR) in TKI‑naive patients increased to 50 months (from 44 months), prompting an sNDA submission to update the label (company expects to submit imminently). IBTROZI demonstrated robust intracranial activity and an 80% confirmed ORR post-entrectinib failure in a small subgroup. Life‑cycle and geographic progress: TRUST‑IV (adjuvant Phase III) initiated; Japanese approval received with an expected reimbursement-based $25M milestone and upcoming royalties; ex‑U.S. partnering discussions (Europe) are advanced. Pipeline update: safusidenib (mutant IDH1 inhibitor) is being advanced into a global, randomized, registration‑enabling Phase III maintenance study in high‑grade IDH1‑mutant glioma (~300 patients planned, estimated completion 2029); company will not pursue a costly head‑to‑head low‑grade study against vorasidenib at this time. NUV‑1511 (DDC platform) Phase I data are expected in the near term. Financials and runway: Q3 R&D $28.8M, SG&A $37.4M; cash, cash equivalents and marketable securities $549M plus $50M available under a term loan; management states cash is sufficient to fund operations through profitability. Management emphasized early launch momentum, strong physician uptake (academic and community), testing expansion potential (RNA testing could expand annual incidence to ~4,000 U.S. patients), and a strategy focused on patient starts and durable on‑therapy prevalence rather than near‑term revenue guidance.